Creatine Supplementation and Resistance Training in Patients With Breast Cancer

NCT05878106 | Recruiting

• 1 other identifier: CaRTiC
• Study Type: interventional
• Target: 120
• Locations: 1 country
• Sites: 1

Brief Summary

Background: Creatine supplementation is an effective ergogenic nutrient for athletes, as well as people for people starting a health or fitness program. Resistance training previously been identified as an important method of increasing muscle mass and strength among people, specially in people with cancer to avoid sarcopenia. The potential of creatine supplementation for adaptations produced by strength training in cancer patients are still unknown. Objective: the primary aim of this study is to evaluate the effectiveness of a 16-week supervised resistance training program intervention with and without creatine supplementation in patients with breast cancer. Methods: A multicentre, randomized, double-blind, placebo-controlled study designed to evaluate the effects of creatine supplementation in addition to resistance training in breast cancer patients. Patients will be randomly assigned to 3 groups: a control group (CG) and two experimental groups. The first resistance training group (RG) will perform resistance training, while the second resistance-creatine experimental group (RCG) will perform the same resistance training as the RG and will also receive a 5 g/day supplementation of creatine for the duration of the exercise the 16-week intervention. RG participants will follow the same daily dosing protocol, but in their case, with dextrose/maltodextrin. Resistance training will be a 16-week supervised workout that will consist of a series of resistance exercises (leg press, knee extension, knee bends, chest press, sit-ups, back extensions, pull-ups, and shoulder press) that involved the largest muscle groups of the body and will be performed three times a week on non-consecutive days. Both the RG and the RCG will receive a supplement of soluble protein powder (20-30 g) daily. Discussion: The results of this intervention will help to better understand the potential of non-pharmacological treatment for improving strength and wellbeing values in breast cancer patients with and without creatine supplementation.

Conditions

Breast Cancer; Supplementation; Resistance Training; Physical Performance; Quality of Life

Outcome Measures

Primary Outcomes (3)

• Change in maximal resistance (upper and lower body)

  The maximal resistance in the upper and lower body will be measured in terms of the 5-repetition maximum test (5RM) (i.e. the maximum load that can be lifted five times) in chest and leg press exercises, respectively. Also a handgrip dynamometry test will be used to measure grip resistance.

  7 months follow up. Measures at 0, 2, 4 and 7 months.

• Genetic study

  Saliva samples will be taken from the participants using buccal swabs (4N6FLOQSwab, Life Technologies, Carlsbad, CA). The genetic analysis will be performed using Biomark HD system microfluidic analysis technology (Fluidigm, South San Francisco, CA). From that analysis DNA will be extracted using the QIAmp DNA Mini kit (Qiagen, Hilden, Germany) and will be quantified fluorometrically using Qubit (LifeTechnologies).

  Month 0

• Change in Micro RNA (mRNA)

  A 5/10 ml of urine will be collected in a 15 ml sterile plastic universal container tube kept at room temperature no more than 60 minutes, then stored at -20°C. Total RNA will be extracted from 400 μl of urine by using miRNeasy Serum/Plasma Kit (QIAGEN).

  Month 0 and 4

Secondary Outcomes (8)

• Change in Physical function (walking)

  7 months follow up. Measures at 0, 2, 4 and 7 months.

• Change in Physical function (sitting)

  7 months follow up. Measures at 0, 2, 4 and 7 months.

• Change in Body composition

  7 months follow up. Measures at 0, 2, 4 and 7 months.

• Change in dietary pattern

  7 months follow up. Measures at 0, 2, 4 and 7 months.

• Change in Gastrointestinal discomfort

  7 months follow up. Measures at 0, 2, 4 and 7 months.

Study Arms (3)

Control Group

NO INTERVENTION

They receive physical activity and nutrition recommendations.

Resistance training group

EXPERIMENTAL

They will perform resistance training and placebo in the supplementation.

Other: Resistance training

Resistance training and creatine supplementation group

EXPERIMENTAL

They will perform the same resistance training and will also receive creatine supplementation

Dietary Supplement: Creatine supplementation; Other: Resistance training

Interventions

Creatine supplementation DIETARY_SUPPLEMENT

5 g/day supplementation of creatine for the duration of the exercise the 16-week intervention. The RG and the RCG will receive a supplement of soluble protein powder (20-30 g) daily.

Resistance training and creatine supplementation group

Resistance training OTHER

They will do resistance training. Resistance training will be a 16-week supervised workout that will consist of a series of resistance exercises (leg press, knee extension, knee bends, chest press, sit-ups, back extensions, pull-ups, and shoulder press) that involved the largest muscle groups of the body and will be performed three times a week on non-consecutive days.

Resistance training and creatine supplementation group; Resistance training group

Eligibility Criteria

• Age: 18 Years - 60 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Stage pTis-T1-T2-T3 pN0-1 M0 (early stage).
• Patients who have completed local treatment \[surgery + radiotherapy (RT)\] undergoing clinical follow-up in outpatient clinics with or without adjuvant hormone therapy treatment.
• Age: ≥18-60 years.
• ECOG Performance status from 0 to 1 (IK ≥80%).
• Body mass index above than 18.5.
• Without excessive alcohol consumption (men \> 21 and women \> 14 units/week).
• No current or previous illness or injury that may prevent participation and training.
• No recent systematic strength training.
• Not taking medications that are known to alter body composition (corticosteroids, metformin...).
• People who carry out some aerobic training will not be excluded (the activity carried out will be recorded weekly).

You may not qualify if:

• Having received adjuvant or neoadjuvant chemotherapy.
• Metastatic carcinoma of the breast.
• Recurrence or second primary breast.
• History of previous cancer except previously treated basal cell carcinoma of the skin.
• Decompensated heart disease, uncontrolled hypertension (TAS\>200 or TAD\>110), heart failure (NYHA II or greater), heart failure or constrictive pericarditis, neutropenia, severe anemia (Hb\<8.0 g/dl), blood count platelets \<50,000 microL.
• Other health problems in which exercise is contraindicated
• Perform regular physical activity (150 min/week of moderate activity or 75 of vigorous activity), measured with the PVS questionnaire.
• Pregnancy.
• Criterion in the opinion of the investigator of inability to adequately understand the involvement and participation in this clinical study.

Sponsors & Collaborators

• University of Deusto: lead
• Hospital de Cruces: collaborator
• Hospital de Basurto: collaborator
• Poznan University of Medical Sciences: collaborator
• Hospital Universitario de Burgos: collaborator
• University of Calabria: collaborator

Study Sites (1)

Hospital de Cruces

Bilbao, Bizkaia, 48080, Spain

RECRUITING

Related Publications (33)

• Boidin M, Dawson EA, Thijssen DHJ, Erskine RM. VEGFA rs2010963 GG genotype is associated with superior adaptations to resistance versus endurance training in the same group of healthy, young men. Mol Genet Genomics. 2023 Jan;298(1):119-129. doi: 10.1007/s00438-022-01965-4. Epub 2022 Nov 3.

  PMID: 36326960 BACKGROUND

• Brosnan ME, Brosnan JT. The role of dietary creatine. Amino Acids. 2016 Aug;48(8):1785-91. doi: 10.1007/s00726-016-2188-1. Epub 2016 Feb 13.

  PMID: 26874700 BACKGROUND

• Buford TW, Kreider RB, Stout JR, Greenwood M, Campbell B, Spano M, Ziegenfuss T, Lopez H, Landis J, Antonio J. International Society of Sports Nutrition position stand: creatine supplementation and exercise. J Int Soc Sports Nutr. 2007 Aug 30;4:6. doi: 10.1186/1550-2783-4-6. No abstract available.

  PMID: 17908288 BACKGROUND

• Campos-Ferraz PL, Gualano B, das Neves W, Andrade IT, Hangai I, Pereira RT, Bezerra RN, Deminice R, Seelaender M, Lancha AH. Exploratory studies of the potential anti-cancer effects of creatine. Amino Acids. 2016 Aug;48(8):1993-2001. doi: 10.1007/s00726-016-2180-9. Epub 2016 Feb 12.

  PMID: 26872655 BACKGROUND

• Candow DG, Forbes SC, Chilibeck PD, Cornish SM, Antonio J, Kreider RB. Effectiveness of Creatine Supplementation on Aging Muscle and Bone: Focus on Falls Prevention and Inflammation. J Clin Med. 2019 Apr 11;8(4):488. doi: 10.3390/jcm8040488.

  PMID: 30978926 BACKGROUND

• Chen JF, Tao Y, Li J, Deng Z, Yan Z, Xiao X, Wang DZ. microRNA-1 and microRNA-206 regulate skeletal muscle satellite cell proliferation and differentiation by repressing Pax7. J Cell Biol. 2010 Sep 6;190(5):867-79. doi: 10.1083/jcb.200911036.

  PMID: 20819939 BACKGROUND

• Cornelissen VA, Defoor JG, Stevens A, Schepers D, Hespel P, Decramer M, Mortelmans L, Dobbels F, Vanhaecke J, Fagard RH, Vanhees L. Effect of creatine supplementation as a potential adjuvant therapy to exercise training in cardiac patients: a randomized controlled trial. Clin Rehabil. 2010 Nov;24(11):988-99. doi: 10.1177/0269215510367995. Epub 2010 Jun 24.

  PMID: 20576665 BACKGROUND

• Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyere O, Cederholm T, Cooper C, Landi F, Rolland Y, Sayer AA, Schneider SM, Sieber CC, Topinkova E, Vandewoude M, Visser M, Zamboni M; Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019 Jan 1;48(1):16-31. doi: 10.1093/ageing/afy169.

  PMID: 30312372 BACKGROUND

• Dolan E, Artioli GG, Pereira RMR, Gualano B. Muscular Atrophy and Sarcopenia in the Elderly: Is There a Role for Creatine Supplementation? Biomolecules. 2019 Oct 23;9(11):642. doi: 10.3390/biom9110642.

  PMID: 31652853 BACKGROUND

• Erskine RM, Williams AG, Jones DA, Stewart CE, Degens H. The individual and combined influence of ACE and ACTN3 genotypes on muscle phenotypes before and after strength training. Scand J Med Sci Sports. 2014 Aug;24(4):642-8. doi: 10.1111/sms.12055. Epub 2013 Feb 5.

  PMID: 23384112 BACKGROUND

• Fairman CM, Kendall KL, Newton RU, Hart NH, Taaffe DR, Chee R, Tang CI, Galvao DA. Examining the effects of creatine supplementation in augmenting adaptations to resistance training in patients with prostate cancer undergoing androgen deprivation therapy: a randomised, double-blind, placebo-controlled trial. BMJ Open. 2019 Sep 20;9(9):e030080. doi: 10.1136/bmjopen-2019-030080.

  PMID: 31542747 BACKGROUND

• Fenech M, El-Sohemy A, Cahill L, Ferguson LR, French TA, Tai ES, Milner J, Koh WP, Xie L, Zucker M, Buckley M, Cosgrove L, Lockett T, Fung KY, Head R. Nutrigenetics and nutrigenomics: viewpoints on the current status and applications in nutrition research and practice. J Nutrigenet Nutrigenomics. 2011;4(2):69-89. doi: 10.1159/000327772. Epub 2011 May 28.

  PMID: 21625170 BACKGROUND

• Gerland L, Baumann FT, Niels T. Resistance Exercise for Breast Cancer Patients? Evidence from the Last Decade. Breast Care (Basel). 2021 Dec;16(6):657-663. doi: 10.1159/000513129. Epub 2021 Jan 28.

  PMID: 35087367 BACKGROUND

• Giallauria F, Cittadini A, Smart NA, Vigorito C. Resistance training and sarcopenia. Monaldi Arch Chest Dis. 2016 Jun 22;84(1-2):738. doi: 10.4081/monaldi.2015.738.

  PMID: 27374049 BACKGROUND

• Hall M, Trojian TH. Creatine supplementation. Curr Sports Med Rep. 2013 Jul-Aug;12(4):240-4. doi: 10.1249/JSR.0b013e31829cdff2.

  PMID: 23851411 BACKGROUND

• Hardee JP, Porter RR, Sui X, Archer E, Lee IM, Lavie CJ, Blair SN. The effect of resistance exercise on all-cause mortality in cancer survivors. Mayo Clin Proc. 2014 Aug;89(8):1108-15. doi: 10.1016/j.mayocp.2014.03.018. Epub 2014 Jun 21.

  PMID: 24958698 BACKGROUND

• Iannone F, Montesanto A, Cione E, Crocco P, Caroleo MC, Dato S, Rose G, Passarino G. Expression Patterns of Muscle-Specific miR-133b and miR-206 Correlate with Nutritional Status and Sarcopenia. Nutrients. 2020 Jan 22;12(2):297. doi: 10.3390/nu12020297.

  PMID: 31979011 BACKGROUND

• Kim HJ, Kim CK, Carpentier A, Poortmans JR. Studies on the safety of creatine supplementation. Amino Acids. 2011 May;40(5):1409-18. doi: 10.1007/s00726-011-0878-2. Epub 2011 Mar 12.

  PMID: 21399917 BACKGROUND

• Kreider RB, Kalman DS, Antonio J, Ziegenfuss TN, Wildman R, Collins R, Candow DG, Kleiner SM, Almada AL, Lopez HL. International Society of Sports Nutrition position stand: safety and efficacy of creatine supplementation in exercise, sport, and medicine. J Int Soc Sports Nutr. 2017 Jun 13;14:18. doi: 10.1186/s12970-017-0173-z. eCollection 2017.

  PMID: 28615996 BACKGROUND

• Kreider RB, Stout JR. Creatine in Health and Disease. Nutrients. 2021 Jan 29;13(2):447. doi: 10.3390/nu13020447.

  PMID: 33572884 BACKGROUND

• Lonbro S, Dalgas U, Primdahl H, Overgaard J, Overgaard K. Feasibility and efficacy of progressive resistance training and dietary supplements in radiotherapy treated head and neck cancer patients--the DAHANCA 25A study. Acta Oncol. 2013 Feb;52(2):310-8. doi: 10.3109/0284186X.2012.741325. Epub 2012 Nov 28.

  PMID: 23190359 BACKGROUND

• Chandrashekhar Iyer L, Vaishali K, Babu AS. Prevalence of sarcopenia in heart failure: A systematic review. Indian Heart J. 2023 Jan-Feb;75(1):36-42. doi: 10.1016/j.ihj.2022.12.004. Epub 2022 Dec 22.

  PMID: 36567064 BACKGROUND

• Norman K, Stubler D, Baier P, Schutz T, Ocran K, Holm E, Lochs H, Pirlich M. Effects of creatine supplementation on nutritional status, muscle function and quality of life in patients with colorectal cancer--a double blind randomised controlled trial. Clin Nutr. 2006 Aug;25(4):596-605. doi: 10.1016/j.clnu.2006.01.014. Epub 2006 May 15.

  PMID: 16701923 BACKGROUND

• Padilha CS, Marinello PC, Galvao DA, Newton RU, Borges FH, Frajacomo F, Deminice R. Evaluation of resistance training to improve muscular strength and body composition in cancer patients undergoing neoadjuvant and adjuvant therapy: a meta-analysis. J Cancer Surviv. 2017 Jun;11(3):339-349. doi: 10.1007/s11764-016-0592-x. Epub 2017 Jan 4.

  PMID: 28054255 BACKGROUND

• Patra S, Ghosh A, Roy SS, Bera S, Das M, Talukdar D, Ray S, Wallimann T, Ray M. A short review on creatine-creatine kinase system in relation to cancer and some experimental results on creatine as adjuvant in cancer therapy. Amino Acids. 2012 Jun;42(6):2319-30. doi: 10.1007/s00726-011-0974-3. Epub 2011 Jul 19.

  PMID: 21769499 BACKGROUND

• Pescatello LS, Kostek MA, Gordish-Dressman H, Thompson PD, Seip RL, Price TB, Angelopoulos TJ, Clarkson PM, Gordon PM, Moyna NM, Visich PS, Zoeller RF, Devaney JM, Hoffman EP. ACE ID genotype and the muscle strength and size response to unilateral resistance training. Med Sci Sports Exerc. 2006 Jun;38(6):1074-81. doi: 10.1249/01.mss.0000222835.28273.80.

  PMID: 16775548 BACKGROUND

• Soares RJ, Cagnin S, Chemello F, Silvestrin M, Musaro A, De Pitta C, Lanfranchi G, Sandri M. Involvement of microRNAs in the regulation of muscle wasting during catabolic conditions. J Biol Chem. 2014 Aug 8;289(32):21909-25. doi: 10.1074/jbc.M114.561845. Epub 2014 Jun 2.

  PMID: 24891504 BACKGROUND

• Stares A, Bains M. The Additive Effects of Creatine Supplementation and Exercise Training in an Aging Population: A Systematic Review of Randomized Controlled Trials. J Geriatr Phys Ther. 2020 Apr/Jun;43(2):99-112. doi: 10.1519/JPT.0000000000000222.

  PMID: 30762623 BACKGROUND

• Zhang G, Li X, Sui C, Zhao H, Zhao J, Hou Y, DU Y. Incidence and risk factor analysis for sarcopenia in patients with cancer. Oncol Lett. 2016 Feb;11(2):1230-1234. doi: 10.3892/ol.2015.4019. Epub 2015 Dec 9.

  PMID: 26893724 BACKGROUND

• Pinheiro PA, Carneiro JA, Coqueiro RS, Pereira R, Fernandes MH. "Chair Stand Test" as Simple Tool for Sarcopenia Screening in Elderly Women. J Nutr Health Aging. 2016 Jan;20(1):56-9. doi: 10.1007/s12603-016-0676-3.

  PMID: 26728934 BACKGROUND

• Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992 Jun;30(6):473-83.

  PMID: 1593914 BACKGROUND

• Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993 Mar 3;85(5):365-76. doi: 10.1093/jnci/85.5.365.

  PMID: 8433390 BACKGROUND

• Cella D, Nowinski CJ. Measuring quality of life in chronic illness: the functional assessment of chronic illness therapy measurement system. Arch Phys Med Rehabil. 2002 Dec;83(12 Suppl 2):S10-7. doi: 10.1053/apmr.2002.36959.

  PMID: 12474167 BACKGROUND

MeSH Terms

Conditions

Breast Neoplasms

Interventions

Creatine; Resistance Training

Condition Hierarchy (Ancestors)

Neoplasms by Site; Neoplasms; Breast Diseases; Skin Diseases; Skin and Connective Tissue Diseases

Intervention Hierarchy (Ancestors)

Guanidines; Amidines; Organic Chemicals; Amino Acids; Amino Acids, Peptides, and Proteins; Exercise Therapy; Rehabilitation; Aftercare; Continuity of Patient Care; Patient Care; Therapeutics; Physical Therapy Modalities; Physical Conditioning, Human; Exercise; Motor Activity; Movement; Musculoskeletal Physiological Phenomena; Musculoskeletal and Neural Physiological Phenomena

Study Officials

• Arkaitz Castañeda, PhD

  University of Deusto

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Arkaitz Castañeda, PhD

CONTACT

944139003; arkaitz.castaneda@deusto.es

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: INVESTIGATOR
• Purpose: SUPPORTIVE CARE
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: April 27, 2023
• First Posted: May 26, 2023
• Study Start: April 8, 2024
• Primary Completion: April 20, 2025
• Study Completion: December 8, 2025
• Last Updated: May 9, 2024

Record last verified: 2024-05

Data Sharing

• IPD Sharing: Will not share

Locations

ES (1)